Nabiximols (Sativex) in chronic spinal cord injury spasticity: prospective study

Introduction and clinical context

The study Nabiximols (Sativex) in chronic spinal cord injury spasticity: prospective study (Spinal Cord Series · 2025) is part of the scientific research on the use of cannabinoids in spinal cord injury.

In spinal cord injury, spasticity and neuropathic pain are among the most disabling symptoms. Nabiximols (Sativex) and vaporized cannabis are studied as options when conventional therapy is not enough, with reports of improvement in spasticity and pain in some patients. The evidence is still limited and use should be monitored by a rehabilitation team.

Understanding what science shows about the use of cannabinoids in spinal cord injury helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This study evaluated the topic based on clinical data. Prospective study: nabiximols in chronic spinal cord injury spasticity refractory to conventional therapy. The findings contribute to the body of evidence and should be interpreted in the context of other studies. Each study adds to the body of evidence guiding the responsible use of cannabinoids.

Mechanism of action and safety

In spinal cord injury, spasticity results from the loss of inhibition over the reflex arc; cannabinoids, such as nabiximols, act on CB1/CB2 receptors, reducing hyperexcitability and modulating the associated neuropathic pain. Regarding safety, dizziness, fatigue and mild psychoactive effects of THC are observed, with attention to interactions with other muscle relaxants and CNS depressants. Gradual introduction and periodic reassessment — seeking the lowest effective dose — guide use, which should integrate into the rehabilitation program.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Spinal Cord Series · 2025). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help in spinal cord injury?

Studies report improvement in refractory spasticity and pain; the evidence is limited and use is monitored.

When is it considered?

Generally when conventional therapy does not control spasticity or pain.